04 Dec 2023
// Zoey Becker FIERCE PHARMA
19 Sep 2023
// Fraiser Kansteiner FIERCE PHARMA
30 Aug 2023
// PRESS RELEASE
Latest Content by PharmaCompass
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #5C41
08-10 October, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Exhibiting
12-14 November, 2024
CPhI India 2024CPhI India 2024
Industry Trade Show
Attending
26-28 November, 2024
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #5C41
08-10 October, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Exhibiting
12-14 November, 2024
CPhI India 2024CPhI India 2024
Industry Trade Show
Attending
26-28 November, 2024
04 Dec 2023
// Zoey Becker FIERCE PHARMA
https://www.fiercepharma.com/pharma/south-africas-aspen-expands-reach-china-100m-buy-sandoz-chinese-business
19 Sep 2023
// Fraiser Kansteiner FIERCE PHARMA
https://www.fiercepharma.com/pharma/following-eli-lilly-novo-nordisk-links-aspen-produce-insulin-africa
30 Aug 2023
// PRESS RELEASE
https://www.aspenpharma.com/aspen-and-lilly-enter-into-agreement-in-south-africa-and-the-rest-of-sub-saharan-africa/
30 Aug 2023
// PRESS RELEASE
https://www.aspenpharma.com/aspen-revenue-exceeds-r40-billion-with-accelerated-medium-term-growth-anticipated/
18 Jul 2023
// PRESS RELEASE
https://www.aspenpharma.com/aspen-hosts-mandela-day-for-13th-consecutive-year-having-reached-865-000-beneficiaries/
18 Jul 2023
// PRESS RELEASE
https://www.aspenpharma.com/aspen-hosts-mandela-day-for-13th-consecutive-year-having-reached-865-000-beneficiaries/
Details:
The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Brand Name: Sandostatin LAR Depot
Study Phase: ApprovedProduct Type: Peptide
Recipient: Sandoz B2B
Deal Size: $99.9 million Upfront Cash: Undisclosed
Deal Type: Agreement December 04, 2023
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Sandoz B2B
Deal Size : $99.9 million
Deal Type : Agreement
Aspen Concludes Two Significant Agreements with Sandoz for China and Europe
Details : The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Brand Name : Sandostatin LAR Depot
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 04, 2023
Details:
PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Lead Product(s): Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Pneumosil
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: Gates Foundation
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 12, 2022
Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Gates Foundation
Deal Size : $30.0 million
Deal Type : Funding
Details : PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Brand Name : Pneumosil
Molecule Type : Vaccine
Upfront Cash : Undisclosed
December 12, 2022
Details:
PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Lead Product(s): 10 Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Pneumosil
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 31, 2022
Lead Product(s) : 10 Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Collaboration
Details : PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countrie...
Brand Name : Pneumosil
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 31, 2022
Details:
EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Brand Name: Eikance
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children
Details : EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.
Brand Name : Eikance
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2022
Details:
Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Brand Name: Trelstar
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 01, 2022
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Debiopharm
Deal Size : Undisclosed
Deal Type : Partnership
Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa
Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...
Brand Name : Trelstar
Molecule Type : Peptide
Upfront Cash : Undisclosed
February 01, 2022
Details:
The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.
Lead Product(s): Ad26.COV2.S
Therapeutic Area: Infections and Infectious Diseases Brand Name: JNJ-78436735
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2021
Lead Product(s) : Ad26.COV2.S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage
Details : The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.
Brand Name : JNJ-78436735
Molecule Type : Vaccine
Upfront Cash : Undisclosed
November 30, 2021
Details:
The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.
Lead Product(s): Esomeprazole Magnesium
Therapeutic Area: Gastroenterology Brand Name: Trustan
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Acino Pharma
Deal Size: $119.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 22, 2021
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Acino Pharma
Deal Size : $119.4 million
Deal Type : Acquisition
Acino Acquires Selected Aspen Brands in South Africa
Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.
Brand Name : Trustan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 22, 2021
Details:
Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.
Lead Product(s): Conjugated Estrogens
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Cenestin
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Avion Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 12, 2020
Lead Product(s) : Conjugated Estrogens
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Avion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals
Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...
Brand Name : Cenestin
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 12, 2020
Details:
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Lead Product(s): Fondaparinux Sodium
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Arixtra
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Viatris
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Viatris
Deal Size : $757.2 million
Deal Type : Acquisition
Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary
Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Brand Name : Arixtra
Molecule Type : Small molecule
Upfront Cash : $310.4 million
September 08, 2020
Details:
The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.
Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology Brand Name: Lidocaine HCl-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sandoz B2B
Deal Size: $440.0 million Upfront Cash: $330.0 million
Deal Type: Acquisition January 31, 2020
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sandoz B2B
Deal Size : $440.0 million
Deal Type : Acquisition
Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world...
Details : The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.
Brand Name : Lidocaine HCl-Generic
Molecule Type : Small molecule
Upfront Cash : $330.0 million
January 31, 2020
Regulatory Info : Originator
Registration Country : South Africa
(Each Unit consists of :-SACHET A x 2) Macrogol (PEG 3350)
Dosage Form : POW
Brand Name : MOVIPREP
Dosage Strength : 100g
Packaging : 1X1g
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : POW
Brand Name : MOVIPREP
Dosage Strength : 4.7g
Packaging : 1X1g
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : LOZ
Brand Name : OROTHROAT PLUS BLACKCURRA...
Dosage Strength : 1,2mg
Packaging : 16X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : LOZ
Brand Name : OROTHROAT PLUS HONEY AND ...
Dosage Strength : 1,2mg
Packaging : 16X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : SOL
Brand Name : Aspen Abacavir 20mg/ml
Dosage Strength : 20mg/ml
Packaging : 240X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : TAB
Brand Name : Aspen Abacavir 300
Dosage Strength : 300mg
Packaging : 60X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : TAB
Brand Name : Butobloc
Dosage Strength : 400mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : SPO
Brand Name : Merthiolate Spray
Dosage Strength : 10ml
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : SPR
Brand Name : Merthiolate
Dosage Strength : 10ml
Packaging : 2500X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : RX
Registration Country : USA
Dosage Form : INJECTABLE;INTRAVENOUS
Brand Name : ACETYLCYSTEINE
Dosage Strength : 6GM/30ML (200MG/ML)
Packaging :
Approval Date : 2022-02-03
Application Number : 213693
Regulatory Info : RX
Registration Country : USA
RLD : No
TE Code : AP
Dosage Form : INJECTABLE; INTRAVENOUS
Proprietary Name : ACETYLCYSTEINE
Dosage Strength : 6GM/30ML (200MG/ML)
Approval Date : 2022-02-03
Application Number : 213693
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : ORGARAN
Dosage Strength : 750 UNITS/0.6ML
Approval Date : 1996-12-24
Application Number : 20430
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code : AB
DESOGESTREL; ETHINYL ESTRADIOL
Dosage Form : TABLET; ORAL-28
Proprietary Name : CYCLESSA
Dosage Strength : 0.1MG,0.125MG,0.15MG;0.0...
Approval Date : 2000-12-20
Application Number : 21090
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : No
TE Code :
Dosage Form : ELIXIR; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 0.5MG/5ML
Approval Date : 1982-01-01
Application Number : 12674
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 0.5MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 0.75MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 1.5MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 4MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
DEXAMETHASONE SODIUM PHOSPHATE
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : HEXADROL
Dosage Strength : EQ 4MG PHOSPHATE/ML **Fe...
Approval Date : 1982-01-01
Application Number : 14694
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
DEXAMETHASONE SODIUM PHOSPHATE
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : HEXADROL
Dosage Strength : EQ 10MG PHOSPHATE/ML **F...
Approval Date : 1982-01-01
Application Number : 14694
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Tabl
Dosage Strength : 100mg
Packaging :
Brand Name : Zyloric 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Tabl
Dosage Strength : 300mg
Packaging :
Brand Name : Zyloric 300
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Tabl
Dosage Strength : 300mg
Packaging :
Brand Name : Zyloric 300
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Dosage Form : Film-Coated Tablets
Dosage Strength : 50 mg
Packaging : 50 UNITS 50 MG - O...
Brand Name : AZATIOPRINE ASPEN
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtabl
Dosage Strength : 50mg
Packaging :
Brand Name : Imurek
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtabl
Dosage Strength : 50mg
Packaging :
Brand Name : Imurek
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Filmtable
Dosage Strength : 25mg
Packaging :
Brand Name : Imurek
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Dosage Form : Tablet, film-coated
Dosage Strength : 25 mg
Packaging : Blisterpakning ...
Brand Name : Imurel
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Dosage Form : Tablet, film-coated
Dosage Strength : 50 mg
Packaging : Blisterpakning ...
Brand Name : Imurel
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Film-Coated Tablets
Dosage Strength : 2mg
Packaging :
Brand Name : Leukeran
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : TABLET
Dosage Strength : 50MG
Packaging : 100/250/500/1000
Brand Name : IMURAN
Approval Date :
Application Number : 4596
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 10ML/VIAL
Packaging : 10ML
Brand Name : ALKERAN
Approval Date :
Application Number : 2087286
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 2.5MG/ML
Packaging : 10/20 ML
Brand Name : SENSORCAINE
Approval Date :
Application Number : 1976141
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 2.5MG/ML
Packaging : 20ML
Brand Name : SENSORCAINE WITH EPINEPHRINE
Approval Date :
Application Number : 1976184
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 5MG/ML
Packaging : 20ML
Brand Name : SENSORCAINE WITH EPINEPHRINE
Approval Date :
Application Number : 1976206
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 5MG/ML
Packaging : 10/20 ML
Brand Name : SENSORCAINE
Approval Date :
Application Number : 1976168
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : TABLET
Dosage Strength : 2MG
Packaging : 25
Brand Name : MYLERAN
Approval Date :
Application Number : 4618
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : TABLET
Dosage Strength : 2MG
Packaging : 25
Brand Name : LEUKERAN
Approval Date :
Application Number : 4626
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 750UNIT/0.6ML
Packaging : 10X0.6ML AMPS
Brand Name : ORGARAN
Approval Date :
Application Number : 2129043
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : TABLET
Dosage Strength : 0.1MG
Packaging : 21
Brand Name : LINESSA 21
Approval Date :
Application Number : 2272903
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 60
Brand Name : Eskazole
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 6
Brand Name : Zentel
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 6
Brand Name : Zentel
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 10
Brand Name : Alprax 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 10
Brand Name : Alprax 0.5
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
amiloride + hydrochlorothiazide
Dosage Form : Tablet; Tablet
Dosage Strength : 5MG; 50MG
Packaging : 50
Brand Name : Moduretic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
amiloride + hydrochlorothiazide
Dosage Form : Tablet; Tablet
Dosage Strength : 5MG; 50MG
Packaging : 50
Brand Name : Moduretic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : tablet
Dosage Strength : 5 mg
Packaging : 30
Brand Name : Norvasc
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : tablet
Dosage Strength : 10 mg
Packaging : 30
Brand Name : Norvasc
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : tablet
Dosage Strength : 5 mg
Packaging : 30
Brand Name : Norvasc
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Originator
Registration Country : South Africa
(Each Unit consists of :-SACHET A x 2) Macrogol (PEG 3350)
Dosage Form : POW
Dosage Strength : 100g
Packaging : 1X1g
Brand Name : MOVIPREP
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : POW
Dosage Strength : 4.7g
Packaging : 1X1g
Brand Name : MOVIPREP
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : LOZ
Dosage Strength : 1,2mg
Packaging : 16X1mg
Brand Name : OROTHROAT PLUS BLACKCURRANT L...
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : LOZ
Dosage Strength : 1,2mg
Packaging : 16X1mg
Brand Name : OROTHROAT PLUS HONEY AND LEMO...
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : SOL
Dosage Strength : 20mg/ml
Packaging : 240X1mg/ml
Brand Name : Aspen Abacavir 20mg/ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : TAB
Dosage Strength : 300mg
Packaging : 60X1mg
Brand Name : Aspen Abacavir 300
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : TAB
Dosage Strength : 400mg
Packaging : 30X1mg
Brand Name : Butobloc
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : SPR
Dosage Strength : 10ml
Packaging : 2500X1mg
Brand Name : Merthiolate
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Dosage Form : SPO
Dosage Strength : 10ml
Packaging : 30X1mg
Brand Name : Merthiolate Spray
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Dosage Form : EFT
Dosage Strength : 200mg
Packaging : 40X1mg
Brand Name : Tussmuco
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?